RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

This study is testing a new experimental medicine called RMC-6236 to see if it works better than standard chemotherapy for treating pancreatic cancer that has spread. Researchers hope this new drug can better block the specific protein that helps these cancer cells grow.

This study is for adults over 18 who have been diagnosed with pancreatic cancer that has spread to other parts of the body. You must be able to carry out your daily activities and have blood tests showing your liver and kidneys are functioning well.

Participants will be assigned to receive either the new study drug or a standard chemotherapy treatment chosen by their doctor. You will have regular appointments and medical scans, like CT or MRI, to see how the treatment is affecting your tumor and how your body responds.

This study is currently active but is not enrolling new patients at this time. It is being conducted at medical centers in Gilbert and Phoenix, Arizona, and Duarte, California.